This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Comparative Approaches in Treating Double-J Stent Syndrome: Monotherapy or Combination Therapy?
by
Cătălin Pricop
Cătălin Pricop 1,2,
Carina Alexandra Bandac
Carina Alexandra Bandac 2,*,
Marius Ivanuță
Marius Ivanuță 1,2,*,
Daniel Rădăvoi
Daniel Rădăvoi 3,4,
Viorel Jinga
Viorel Jinga 3,4
and
Dragoş Puia
Dragoş Puia 1,2
1
“Grigore T Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
2
Department of Urology, “Dr. C.I. Parhon” Clinical Hospital, 700503 Iasi, Romania
3
Department of Urology, “Theodor Burghele” Clinical Hospital, 050653 Bucharest, Romania
4
“Carol Davila” University of Medicine and Pharmacy, 050653 Bucharest, Romania
*
Authors to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(14), 4278; https://doi.org/10.3390/jcm13144278 (registering DOI)
Submission received: 17 June 2024
/
Revised: 8 July 2024
/
Accepted: 18 July 2024
/
Published: 22 July 2024
Abstract
Introduction: The application of double-J ureteral stents in urology is widespread, but their use is often accompanied by complications and bothersome symptoms, affecting patients’ quality of life (QoL). While various medications have been tested for alleviating the symptoms associated with double-J stents, consensus on their effectiveness remains elusive. This study aims to investigate the effectiveness of tamsulosin, solifenacin, mirabegron, desloratadine, and combination therapy using a Romanian-adapted version of the Ureteral Stent Symptom Questionnaire (USSQ). Materials and Methods: A prospective, observational, randomised trial was conducted at the Urology and Renal Transplant Clinic of Dr. “C.I. Parhon” Clinical Hospital in Iasi between 1 January 2022 and 1 August 2023. Three hundred twenty seven patients who underwent their first double-J stent insertion were evaluated with the Romanian-adapted USSQ at baseline and 30 days post-insertion. Patients were randomly divided into six groups based on the prescribed medications: control, tamsulosin, mirabegron, solifenacin, desloratadine, and combination therapy. Results: The data suggest a significant reduction in symptoms in patients who received medication compared with the control group. Furthermore, the combined medication of solifenacin 10 mg and tamsulosin 0.4 mg was particularly effective in reducing pain with statistical significance compared to the control group (p = 0.001). The highest mean scores for urinary symptom severity were observed in the control group (12.37 ± 6.82), and the lowest was in the mirabegron group (9.94 ± 5.82). The individuals who received a daily dose of 50 mg of mirabegron saw the most notable influence on their job. Conclusions: While no single medication emerged as a “miracle drug” for managing symptoms related to double-J stent insertion, the combination therapy of solifenacin and tamsulosin is the most promising option for improving symptoms related to double-J stent insertion and QoL. Additional extensive research is required to validate these initial results.
Share and Cite
MDPI and ACS Style
Pricop, C.; Bandac, C.A.; Ivanuță, M.; Rădăvoi, D.; Jinga, V.; Puia, D.
Comparative Approaches in Treating Double-J Stent Syndrome: Monotherapy or Combination Therapy? J. Clin. Med. 2024, 13, 4278.
https://doi.org/10.3390/jcm13144278
AMA Style
Pricop C, Bandac CA, Ivanuță M, Rădăvoi D, Jinga V, Puia D.
Comparative Approaches in Treating Double-J Stent Syndrome: Monotherapy or Combination Therapy? Journal of Clinical Medicine. 2024; 13(14):4278.
https://doi.org/10.3390/jcm13144278
Chicago/Turabian Style
Pricop, Cătălin, Carina Alexandra Bandac, Marius Ivanuță, Daniel Rădăvoi, Viorel Jinga, and Dragoş Puia.
2024. "Comparative Approaches in Treating Double-J Stent Syndrome: Monotherapy or Combination Therapy?" Journal of Clinical Medicine 13, no. 14: 4278.
https://doi.org/10.3390/jcm13144278
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article metric data becomes available approximately 24 hours after publication online.